| Schedule of Segment Reporting Information, by Segment [Table Text Block] | 
    
|   | 
  | 
  Year Ended June 30,   | 
  | 
 
|   | 
  | 
  2020   | 
  | 
  | 
2019 | 
  | 
  | 
2018 | 
  | 
 
|   Net sales:   | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
 
|   Protein Sciences   | 
  | 
$ | 
555,352 | 
  | 
  | 
$ | 
543,159 | 
  | 
  | 
$ | 
482,378 | 
  | 
 
|   Diagnostics and Genomics   | 
  | 
  | 
184,549 | 
  | 
  | 
  | 
171,674 | 
  | 
  | 
  | 
161,151 | 
  | 
 
|   Intersegment   | 
  | 
  | 
(1,210 | 
  )   | 
  | 
  | 
(827 | 
  )   | 
  | 
  | 
(536 | 
  )   | 
 
|   Consolidated net sales   | 
  | 
$ | 
738,691 | 
  | 
  | 
$ | 
714,006 | 
  | 
  | 
$ | 
642,993 | 
  | 
 
|   | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
 
|   Operating Income:   | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
 
|   Protein Sciences   | 
  | 
$ | 
234,929 | 
  | 
  | 
$ | 
240,919 | 
  | 
  | 
$ | 
209,880 | 
  | 
 
|   Diagnostics and Genomics   | 
  | 
  | 
14,965 | 
  | 
  | 
  | 
10,079 | 
  | 
  | 
  | 
35,496 | 
  | 
 
|   Segment operating income   | 
  | 
  | 
249,894 | 
  | 
  | 
  | 
250,998 | 
  | 
  | 
  | 
245,376 | 
  | 
 
|   Costs recognized upon sale of acquired inventory   | 
  | 
  | 
- | 
      | 
  | 
  | 
(3,739 | 
  )   | 
  | 
  | 
(2,455 | 
  )   | 
 
|   Amortization of acquired intangible assets   | 
  | 
  | 
(60,865 | 
  )   | 
  | 
  | 
(58,550 | 
  )   | 
  | 
  | 
(46,983 | 
  )   | 
 
| Gain on escrow settlement | 
  | 
  | 
7,169 | 
  | 
  | 
  | 
- | 
  | 
  | 
  | 
- | 
  | 
 
|   Acquisition related expenses   | 
  | 
  | 
(416 | 
  )   | 
  | 
  | 
(2,282 | 
  )   | 
  | 
  | 
(24,429 | 
  )   | 
 
|   Restructuring costs   | 
  | 
  | 
(87 | 
  )   | 
  | 
  | 
- | 
      | 
  | 
  | 
(376 | 
) | 
 
|   Stock-based compensation   | 
  | 
  | 
  (34,262   | 
  )   | 
  | 
  | 
(33,057 | 
  )   | 
  | 
  | 
(28,240 | 
  )   | 
 
|   Corporate general, selling and administrative expenses   | 
  | 
  | 
(4,015 | 
  )   | 
  | 
  | 
(6,651 | 
  )   | 
  | 
  | 
(6,715 | 
  )   | 
 
|   Consolidated operating income   | 
  | 
$ | 
157,419 | 
  | 
  | 
$ | 
146,719 | 
  | 
  | 
$ | 
136,178 | 
  | 
 
 
    
|   | 
  | 
  Year Ended June 30,   | 
  | 
 
|   | 
  | 
  2020   | 
  | 
  | 
2019 | 
  | 
  | 
  2018   | 
  | 
 
| Consumables revenue - Protein Sciences | 
  | 
$ | 
  431,052   | 
  | 
  | 
$ | 
430,655 | 
  | 
  | 
$ | 
384,350 | 
  | 
 
|   Consumables revenue - Diagnostics and Genomics   | 
  | 
  | 
171,590 | 
  | 
  | 
  | 
158,324 | 
  | 
  | 
  | 
150,388 | 
  | 
 
|   Total consumable revenue   | 
  | 
$ | 
602,642 | 
  | 
  | 
$ | 
588,979 | 
  | 
  | 
$ | 
534,738 | 
  | 
 
 
    
|   | 
  | 
  Year ended June 30,   | 
  | 
 
|   Long-lived assets:   | 
  | 
  2020   | 
  | 
  | 
2019 | 
  | 
 
|   United States and Canada   | 
  | 
$ | 
162,039 | 
  | 
  | 
$ | 
138,016 | 
  | 
 
|   Europe   | 
  | 
  | 
13,120 | 
  | 
  | 
  | 
14,439 | 
  | 
 
|   Asia   | 
  | 
  | 
1,670 | 
  | 
  | 
  | 
1,584 | 
  | 
 
|   Total long-lived assets   | 
  | 
$ | 
176,829 | 
  | 
  | 
$ | 
154,039 | 
  | 
 
|   Intangible assets:   | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
  | 
 
|   United States and Canada   | 
  | 
$ | 
499,875 | 
  | 
  | 
$ | 
556,951 | 
  | 
 
|   Europe   | 
  | 
  | 
12,349 | 
  | 
  | 
  | 
16,637 | 
  | 
 
|   Asia   | 
  | 
  | 
4,321 | 
  | 
  | 
  | 
5,841 | 
  | 
 
|   Total intangible assets   | 
  | 
$ | 
516,545 | 
  | 
  | 
$ | 
579,429 | 
  | 
 
 
   
 |